Login to Your Account

Amgen to carry Cytokinetics HF drug into phase III

By Michael Fitzhugh
Staff Writer

Friday, September 2, 2016

A long-awaited global phase III study of Cytokinetics Inc.'s chronic heart failure drug omecamtiv mecarbil, funded and run by partner Amgen Inc., is on track to start during the fourth quarter, the companies said.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription